Filing Details

Accession Number:
0000899243-17-022645
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-09-27 16:05:34
Reporting Period:
2017-09-25
Accepted Time:
2017-09-27 16:05:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1559053 Prothena Corp Plc PRTA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1564461 Tara Nickerson C/O Prothena Biosciences Inc
331 Oyster Point Boulevard
South San Francisco CA 94080
Chief Business Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares, Par Value $0.01 Per Share Acquisiton 2017-09-25 17,500 $6.41 19,500 No 4 M Direct
Ordinary Shares, Par Value $0.01 Per Share Disposition 2017-09-25 13,717 $63.39 5,783 No 4 S Direct
Ordinary Shares, Par Value $0.01 Per Share Disposition 2017-09-25 3,783 $64.33 2,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Stock Option(right to buy) Disposition 2017-09-25 17,500 $0.00 17,500 $6.41
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,500 2023-01-29 No 4 M Direct
Footnotes
  1. The sales reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
  2. The transaction was executed in multiple trades in prices ranging from $62.90 to $63.89, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  3. The transaction was executed in multiple trades in prices ranging from $63.93 to $64.71, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  4. The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on January 29, 2014 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.